Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2001 • 877 citations

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

2001 • 821 citations

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

2005 • 446 citations

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

2003 • 304 citations

Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

2001 • 278 citations

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

2002 • 240 citations

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

2003 • 184 citations

Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia

2002 • 176 citations

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia

2005 • 153 citations

The Research on Adverse Drug Events and Reports (RADAR) Project

2005 • 126 citations

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

2003 • 107 citations

Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis

2003 • 99 citations

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes

2003 • 81 citations

The role of gemtuzumab ozogamicin in acute leukaemia therapy

2005 • 79 citations

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

2002 • 76 citations

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

2003 • 73 citations

Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell Transplantation

2001 • 73 citations

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

2003 • 72 citations

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

2002 • 62 citations

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

2003 • 58 citations

Management of Hepatic Sinusoidal Obstruction Syndrome Following Treatment with Gemtuzumab Ozogamicin (Mylotarg®)

2002 • 41 citations

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

2003 • 32 citations

Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease

2004 • 27 citations